Rapamycin (Sirolimus) Bone Health and Density Impact

What does the Rapamune label say about bone?

Rapamune is an mTOR inhibitor immunosuppressant approved for prophylaxis of organ rejection in renal transplant patients aged 13 and older, and for lymphangioleiomyomatosis (LAM) [1]. Its labeled risks include infection and malignancy, hypersensitivity reactions, angioedema, fluid accumulation and impaired wound healing, hyperlipidemia, decline in renal function, proteinuria, interstitial lung disease, calcineurin-inhibitor-associated HUS/TTP/TMA, embryo-fetal toxicity, male infertility and avoidance of live vaccines [1]. Bone mineral density loss, osteoporosis and fracture are not among them.

The label's adverse-reaction section does include one bone term. Bone necrosis appears in the list of reactions reported in at least 3% but less than 20% of renal transplant patients taking Rapamune [1]. Those patients were receiving daily sirolimus alongside cyclosporine and corticosteroids [1], so the observation comes from transplant-dose exposure, not from weekly low-dose use.

What human bone data exist at low, intermittent doses?

The PEARL trial is the human study that comes closest to the off-label longevity pattern. It was a 48-week, decentralized, double-blind, placebo-controlled randomized trial (NCT04488601) in healthy, normative-aging adults who received placebo, 5 mg or 10 mg of compounded rapamycin once weekly [2]. Bone mineral content, measured by DXA, was one of the secondary outcomes, alongside blood biomarkers and lean tissue [2].

The reported results: adverse and serious adverse events were similar across groups, visceral adiposity did not change (p = 0.942), lean tissue mass improved in women taking 10 mg (p = 0.013), self-reported pain improved in women taking 10 mg (p = 0.015), emotional well-being improved on 5 mg (p = 0.023) and general health improved on 5 mg (p = 0.004), with no other significant effects observed [2]. Bone mineral content was not among the outcomes reported as significantly changed. The authors concluded that weekly low-dose rapamycin was relatively safe over 48 weeks, and that efficacy for healthspan was not established [2].

Transplant doses and longevity doses are different exposures

The label's regimens are daily and trough-targeted: a 6 mg loading dose then 2 mg daily with cyclosporine and corticosteroids at low-to-moderate immunologic risk, up to a 15 mg loading dose then 5 mg daily for the first 12 months in high-risk patients, and an initial 2 mg daily for LAM [1]. PEARL used 5 mg or 10 mg once weekly [2].

Longevity use falls outside the labeled indications [1]. PEARL used a compounded product [2]; compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing [3].

What is not known

The PEARL abstract reports no fracture outcome and no hip or spine bone mineral density result [2]. Whether daily sirolimus adds bone risk beyond that from corticosteroids and pre-existing kidney disease in transplant patients is not answered by the label's adverse-reaction data [1].

Bottom line

The Rapamune label carries no bone-density warning, though it lists bone necrosis among less common reactions in renal transplant patients on daily combination therapy [1]. The longest human bone measurement at intermittent low doses, 48 weeks of 5 mg or 10 mg weekly in PEARL, did not report a significant change in DXA bone mineral content [2].